Skip to content

Netherlands logo

Main menu
    • About us
    • Our focus
    • Our products
    • Business development
    • Our leaders
    • Our culture
    • Policies & positions
    • Environmental, social & governance
    • Diversity, equity, inclusion & belonging
    • News
    • Media
  • Join our team

Contact Us

Back
Change Language
  • Nederlands
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Organon invests 40 million euros in expansion of production

Save Print

April 12, 2022 6:35 am EDT

OSS – Organon is going to significantly expand the production of long-acting contraception in the Netherlands again. The name Organon officially returned last year and since then the company has entered into various collaborations and acquisitions worldwide to expand its portfolio of medicines and other health solutions. In order to be able to meet the promise that the company made at the start last year: improving the health of women. This is followed by substantial investments in Organon’s largest production site in the world, in Oss.

At the start of Organon in June 2021, it was already clear that the ‘birthplace’ Oss will continue to play an important role in the new company. In Oss, Organon has a rich history in the production of contraception, high-quality innovative technology and a huge distribution network for reliable and continuous delivery to 140 countries in the world. 1,150 of Organon’s more than 9,000 employees worldwide work here. The production facility in Oss is the largest of the six worldwide and will expand again.

In 2021, a new robot production line for assembly and packaging of contraceptive rods was already put into operation. There is approval now to invest in another robot production line, but also for other innovations. Wenny Raaijmakers (Plant Manager Organon Oss, location director) explains: “The intention is to start using this line within three years. Organon Oss is also investing in new extrusion machines with which the contraceptive rods are made and which will increase the supply to the robot lines.”

Volumes
“We are also going to invest in an extra automated packaging line with which the end product is packed in a box with leaflet. After that, the end product can be delivered to doctors and pharmacists worldwide,” says Wenny Raaijmakers. “And in order to cope with the larger production volumes, logistics routes in the production building are also being adapted and systems for IT and quality control are being improved.”
In order to make room in the current building (behind the now well-known mural) for expansion of the production of the contraceptive rod, the production of the contraceptive ring will be concentrated in the relatively new building ‘CP’. Wenny: “With an ongoing investment, two modernized machine lines will be located there.
All these improvement programs and investments contribute to deliver on the promise of women’s health in the short and long term.” Altogether, Organon is investing approximately 40 million euros in expanding production in Oss.

Family planning

The production facility in Oss is the only location in the world where Organon produces contraceptives. From this location, a dedicated team also works specifically on the guidance and logistics for family planning, especially in Africa and Asia. The use of a product such as the pill is less obvious in these countries. Long-acting contraception may be a solution for women in remote areas who often have to walk for hours to the nearest clinic. Good contacts with global organizations such as the Bill & Melinda Gates Foundation and the World Health Organization (WHO) have been playing an important role for many years in making long-acting contraception more available, especially in Africa, Latin America and Asia.

Innovation

At the start in June 2021, Organon made a promise: listening to women worldwide to better understand their health needs and identify solutions that are urgently needed. Petra Willems, Managing Director of Organon Benelux: “There is a need to address diseases and conditions that only or disproportionately impact women. Our impact will go beyond medicine, contraception and fertility treatments. We know we can do so much more for women and their health. “

VVPM job number Organon Oss investment: NL-NON-110021

What can we help you find?

Search for:
Netherlands logo
  • Forward-Looking Statement
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept